Laniquidar

Cat. No.:	HY-132189
CAS No.:	197509-46-9
Molecular Formula:	$C_{37}H_{36}N_4O_3$
Molecular Weight:	584.71
Target:	P-glycoprotein
Pathway:	Membrane Transporter/Ion Channel
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	Laniquidar (R101933) is a noncompetitive, third generation P-glycoprotein (P-gp) inhibitor with an IC_{50} of 0.51 μM. Laniquidar can be used for modulating multidrug resistance transporters[1]. Laniquidar can also be used for studying acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS)[2]. Laniquidar has limited oral bioavailability[3].
IC_{50} & Target	IC_{50}: 0.51 μM (P-glycoprotein)[1]

REFERENCES

[1]. Luurtsema G, et al. Evaluation of [11C]laniquidar as a tracer of P-glycoprotein: radiosynthesis and biodistribution in rats. Nucl Med Biol. 2009 Aug;36(6):643-9.

[2]. Ross DD. Modulation of drug resistance transporters as a strategy for treating myelodysplastic syndrome. Best Pract Res Clin Haematol. 2004 Dec;17(4):641-51.

[3]. Fox E, et al. Tariquidar (XR9576): a P-glycoprotein drug efflux pump inhibitor. Expert Rev Anticancer Ther. 2007 Apr;7(4):447-59.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA